Search company, investor...



Acquired | Acquired

Total Raised




About iTind

iTind is an Israeli medical device company focused on research, development, manufacture and sale of solutions for the treatment of Benign Prostatic Hyperplasia (BPH). On February 26th, 2021, iTind was acquired by Olympus Corporation.

Headquarters Location

14 Hailan St.

Or Akiva,



Missing: iTind's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: iTind's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing iTind

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iTind is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,917 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

iTind Patents

iTind has filed 5 patents.

The 3 most popular patent topics include:

  • Antiandrogens
  • Male genital surgery
  • Penis
patents chart

Application Date

Grant Date


Related Topics




Mammal male reproductive system, Penis, Urinary system, Dosage forms, Antiandrogens


Application Date


Grant Date



Related Topics

Mammal male reproductive system, Penis, Urinary system, Dosage forms, Antiandrogens



Latest iTind News

Xenia Venture Capital Ltd. Is announcing iTind Procedure for Treatment of BPH, Awarded New Code Payment Rate for the Procedure in the US

Dec 27, 2022

USA - English Share this article Share this article TEL AVIV, Israel, Dec. 27, 2022 /PRNewswire/ -- Xenia Venture Capital Ltd., ( ‎‎ ) an Israeli investment company engaged in the establishment, development, and investment in life sciences startups, has announced that Olympus Corporation, a global medical technology company that acquired Israeli Medi-Tate's iTind Procedure for BPH in May 2021, announced that the Centers for Medicare and Medicaid Services (CMS) would increase payment rates for the iTind procedure performed in the hospital-based outpatient department (HOPD) and Ambulatory Surgical Center (ASC). The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023. "I'm glad about the impressive achievement by Medi-Tate. This development is a huge and long-awaited milestone for the commercialization of the iTind Procedure, which will enable its widespread availability in the US market", said Xenia CEO Eli Sorzon. Xenia Venture Capital is an investment company engaged in investing mainly in life science companies in Israel. Xenia also holds 50% of  VLX , a technological incubator operating under the Israel Innovation Authority (IIA) incubator program. In addition to financing, Xenia provides its companies with top-notch mentoring, business and strategic counseling, fundraising assistance, and exit planning. Since its inception Xenia has invested in over 40 companies, which have attained significant technology and business achievements, resulting in substantial valuation increases, as well as strategic transactions with leading companies in the world, in each relevant field. SOURCE Xenia Venture Capital Ltd. ×

iTind Frequently Asked Questions (FAQ)

  • Where is iTind's headquarters?

    iTind's headquarters is located at 14 Hailan St., Or Akiva.

  • What is iTind's latest funding round?

    iTind's latest funding round is Acquired.

  • How much did iTind raise?

    iTind raised a total of $24M.

  • Who are the investors of iTind?

    Investors of iTind include Olympus, Laborie Medical Technologies and Xenia Venture Capital.

  • Who are iTind's competitors?

    Competitors of iTind include PulmonX, Mobius Therapeutics, Inspire Medical Systems, Galil Medical, AirXpanders and 12 more.

Compare iTind to Competitors

Mobius Therapeutics

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.

NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

Perfuzia Medical

Perfuzia Medical is developing the next generation of medical devices for the treatment of chronic wounds.


Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical develops a bioelectronic medicine platform using a small implanted device that activates the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. The company was founded in 2006 and is based in Santa Clarita, California.


OrthoClear is the technology leader in the clear removable aligner orthodontics market. OrthoClear offers the most advanced method of straightening teeth on the market today. Founded in January 2005, OrthoClear ha

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.